Latest Insider Transactions at Kiniksa Pharmaceuticals, Ltd. (KNSA)
This section provides a real-time view of insider transactions for Kiniksa Pharmaceuticals, Ltd. (KNSA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kiniksa Pharmaceuticals, Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kiniksa Pharmaceuticals, Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
17,000
-14.17%
|
$357,000
$21.04 P/Share
|
|
Nov 18
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+7.69%
|
$10,000
$1.59 P/Share
|
|
Nov 07
2024
|
Richard S Levy |
BUY
Exercise of conversion of derivative security
|
Direct |
1,303
+8.4%
|
-
|
|
Nov 06
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Direct |
89,561
-52.96%
|
$2,059,903
$23.0 P/Share
|
|
Nov 06
2024
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
89,561
+34.62%
|
$89,561
$1.59 P/Share
|
|
Oct 15
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
17,000
-13.39%
|
$442,000
$26.87 P/Share
|
|
Oct 15
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+7.3%
|
$10,000
$1.59 P/Share
|
|
Oct 04
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
82
-0.31%
|
$1,968
$24.48 P/Share
|
|
Oct 04
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
175
+0.65%
|
-
|
|
Oct 04
2024
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
9,460
+1.86%
|
-
|
|
Sep 23
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
17,500
-13.01%
|
$420,000
$24.99 P/Share
|
|
Sep 23
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.92%
|
$10,000
$1.59 P/Share
|
|
Sep 03
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
60,692
-27.64%
|
$1,577,992
$26.61 P/Share
|
|
Sep 03
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
60,692
+17.67%
|
$121,384
$2.83 P/Share
|
|
Sep 03
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
68,506
-39.85%
|
$1,781,156
$26.61 P/Share
|
|
Sep 03
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
68,506
+26.97%
|
$685,060
$10.63 P/Share
|
|
Sep 02
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
329
-1.23%
|
$8,554
$26.74 P/Share
|
|
Sep 02
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
775
+2.81%
|
-
|
|
Sep 02
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
835
-1.58%
|
$21,710
$26.74 P/Share
|
|
Sep 02
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,725
+3.16%
|
-
|
|
Sep 02
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
577
-0.46%
|
$15,002
$26.74 P/Share
|
|
Sep 02
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,964
+1.55%
|
-
|
|
Sep 02
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,177
-3.84%
|
$82,602
$26.74 P/Share
|
|
Sep 02
2024
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,569
+7.36%
|
-
|
|
Sep 02
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
956
-4.0%
|
$24,856
$26.74 P/Share
|
|
Sep 02
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,861
+7.22%
|
-
|
|
Sep 02
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
345
-1.56%
|
$8,970
$26.74 P/Share
|
|
Sep 02
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
994
+4.31%
|
-
|
|
Sep 01
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,755
-9.58%
|
$71,630
$26.74 P/Share
|
|
Sep 01
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,490
+18.42%
|
-
|
|
Sep 01
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,994
-3.75%
|
$51,844
$26.74 P/Share
|
|
Sep 01
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,121
+7.2%
|
-
|
|
Sep 01
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,322
-1.06%
|
$34,372
$26.74 P/Share
|
|
Sep 01
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,499
+3.49%
|
-
|
|
Sep 01
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,967
-9.47%
|
$207,142
$26.74 P/Share
|
|
Sep 01
2024
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,474
+16.38%
|
-
|
|
Sep 01
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,260
-9.3%
|
$58,760
$26.74 P/Share
|
|
Sep 01
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,444
+15.45%
|
-
|
|
Sep 01
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,393
-6.2%
|
$36,218
$26.74 P/Share
|
|
Sep 01
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,089
+15.39%
|
-
|
|
Aug 27
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
17,500
-12.74%
|
$455,000
$26.91 P/Share
|
|
Aug 27
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.78%
|
$10,000
$1.59 P/Share
|
|
Jul 23
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
22,000
-8.86%
|
$572,000
$26.59 P/Share
|
|
Jul 23
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+23.96%
|
$22,000
$1.86 P/Share
|
|
Jul 23
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
24,248
-55.74%
|
$581,952
$24.79 P/Share
|
|
Jul 23
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
24,248
+35.79%
|
$266,728
$11.1 P/Share
|
|
Jul 23
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Direct |
136,124
-30.0%
|
$3,403,100
$25.1 P/Share
|
|
Jul 23
2024
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
136,124
+40.6%
|
$136,124
$1.59 P/Share
|
|
Jul 15
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
480
+2.11%
|
$7,200
$15.65 P/Share
|
|
Jul 15
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
211
+1.13%
|
$3,165
$15.65 P/Share
|